Safety and immunogenicity of a dose-sparing, trivalent inactivated seasonal influenza vaccine containing an advax adjuvant – a phase 1/2 randomised controlled trial Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine for the patients with lung comorbidities; a single center, retrospective, self-controlled case series study Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
Immunogenicity and safety of a novel recombinant pandemic influenza vaccine containing a polysaccharide adjuvant Source: Annual Congress 2010 - Influenza A (H1N1) and other viral infections: therapeutic aspects Year: 2010
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018
A randomised controlled trial comparing the immunogenicity, safety and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a needless injector device versus a traditional pre-filled syringe and needle Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005
Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015
Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
Prime-boost, double-dose immunization and immunity to influenza vaccination in COPD Source: Virtual Congress 2021 – Pneumonia Year: 2021
Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001
Practicalities of human inoculation to establish experimental pneumococcal carriage in vaccine studies Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010
Clinical efficacy of pneumococcal vaccine in COPD patients. preliminary results Source: Eur Respir J 2003; 22: Suppl. 45, 408s Year: 2003
Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016
Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Randomised controlled double blind dose-escalation infant trial of the live-attenuated Mycobacterium tuberculosis vaccine MTBVAC Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019
Novel intradermal influenza vaccine: phase 3 data in targeted adult populations Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008